-DOCSTART- -X- O
The -X- _ O
actual -X- _ O
strategy -X- _ O
to -X- _ O
improve -X- _ O
current -X- _ O
therapies -X- _ O
in -X- _ O
advanced -X- _ O
prostate -X- _ B-Patient
cancer -X- _ I-Patient
involves -X- _ O
targeting -X- _ O
genes -X- _ O
activated -X- _ O
by -X- _ O
androgen -X- _ O
withdrawal -X- _ O
, -X- _ O
either -X- _ O
to -X- _ O
delay -X- _ O
or -X- _ O
prevent -X- _ O
the -X- _ O
emergence -X- _ O
of -X- _ O
the -X- _ O
castration-refractory -X- _ O
phenotype. -X- _ O
However -X- _ O
, -X- _ O
these -X- _ O
genes -X- _ O
are -X- _ O
often -X- _ O
implicated -X- _ O
in -X- _ O
several -X- _ O
physiological -X- _ O
processes -X- _ O
, -X- _ O
and -X- _ O
long-term -X- _ O
inhibition -X- _ O
of -X- _ O
survival -X- _ O
proteins -X- _ O
might -X- _ O
be -X- _ O
accompanied -X- _ O
with -X- _ O
cytotoxic -X- _ O
effects. -X- _ O
To -X- _ O
avoid -X- _ O
this -X- _ O
problem -X- _ O
, -X- _ O
an -X- _ O
alternative -X- _ O
therapeutic -X- _ O
strategy -X- _ O
relies -X- _ O
on -X- _ O
the -X- _ O
identification -X- _ O
and -X- _ O
use -X- _ O
of -X- _ O
compounds -X- _ O
that -X- _ O
disrupt -X- _ O
specific -X- _ O
protein-protein -X- _ O
interactions -X- _ O
involved -X- _ O
in -X- _ O
androgen -X- _ O
withdrawal. -X- _ O
Specifically -X- _ O
, -X- _ O
the -X- _ O
interaction -X- _ O
of -X- _ O
the -X- _ O
chaperone -X- _ O
protein -X- _ O
Hsp27 -X- _ O
with -X- _ O
the -X- _ O
initiation -X- _ O
factor -X- _ O
eIF4E -X- _ O
leads -X- _ O
to -X- _ O
the -X- _ O
protection -X- _ O
of -X- _ O
protein -X- _ O
synthesis -X- _ O
initiation -X- _ O
process -X- _ O
and -X- _ O
enhances -X- _ O
cell -X- _ O
survival -X- _ O
during -X- _ O
cell -X- _ O
stress -X- _ O
induced -X- _ O
by -X- _ O
castration -X- _ O
or -X- _ O
chemotherapy. -X- _ O
Thus -X- _ O
, -X- _ O
in -X- _ O
this -X- _ O
work -X- _ O
we -X- _ O
aimed -X- _ O
at -X- _ O
i -X- _ O
) -X- _ O
identifying -X- _ O
the -X- _ O
interaction -X- _ O
site -X- _ O
of -X- _ O
the -X- _ O
Hsp27 -X- _ O
/ -X- _ O
eIF4E -X- _ O
complex -X- _ O
and -X- _ O
ii -X- _ O
) -X- _ O
interfere -X- _ O
with -X- _ O
the -X- _ O
relevant -X- _ O
protein -X- _ O
/ -X- _ O
protein -X- _ O
association -X- _ O
mechanism -X- _ O
involved -X- _ O
in -X- _ O
castration-resistant -X- _ O
progression -X- _ O
of -X- _ O
prostate -X- _ B-Patient
cancer. -X- _ I-Patient
By -X- _ O
a -X- _ O
combination -X- _ O
of -X- _ O
experimental -X- _ O
and -X- _ O
modeling -X- _ O
techniques -X- _ O
, -X- _ O
we -X- _ O
proved -X- _ O
that -X- _ O
eIF4E -X- _ O
interacts -X- _ O
with -X- _ O
the -X- _ O
C-terminal -X- _ O
part -X- _ O
of -X- _ O
Hsp27 -X- _ O
, -X- _ O
preferentially -X- _ O
when -X- _ O
Hsp27 -X- _ O
is -X- _ O
phosphorylated. -X- _ O
We -X- _ O
also -X- _ O
observed -X- _ O
that -X- _ O
the -X- _ O
loss -X- _ B-Outcome
of -X- _ I-Outcome
this -X- _ I-Outcome
interaction -X- _ I-Outcome
increased -X- _ I-Outcome
cell -X- _ I-Outcome
chemo-and -X- _ I-Outcome
hormone-sensitivity. -X- _ I-Outcome
In -X- _ O
order -X- _ O
to -X- _ O
find -X- _ O
a -X- _ O
potential -X- _ O
inhibitor -X- _ O
of -X- _ O
Hsp27 -X- _ B-Intervention
/ -X- _ I-Intervention
eIF4E -X- _ I-Intervention
interaction -X- _ I-Intervention
, -X- _ O
BRET -X- _ B-Outcome
assays -X- _ I-Outcome
in -X- _ I-Outcome
combination -X- _ I-Outcome
with -X- _ I-Outcome
molecular -X- _ I-Outcome
simulations -X- _ I-Outcome
identified -X- _ I-Outcome
the -X- _ I-Outcome
phenazine -X- _ I-Outcome
derivative -X- _ I-Outcome
14 -X- _ I-Outcome
as -X- _ I-Outcome
the -X- _ I-Outcome
compound -X- _ I-Outcome
able -X- _ I-Outcome
to -X- _ I-Outcome
efficiently -X- _ I-Outcome
interfere -X- _ I-Outcome
with -X- _ I-Outcome
this -X- _ I-Outcome
protein -X- _ I-Outcome
/ -X- _ I-Outcome
protein -X- _ I-Outcome
interaction -X- _ I-Outcome
, -X- _ I-Outcome
thereby -X- _ I-Outcome
inhibiting -X- _ I-Outcome
cell -X- _ I-Outcome
viability -X- _ I-Outcome
and -X- _ I-Outcome
increasing -X- _ I-Outcome
cell -X- _ I-Outcome
death -X- _ I-Outcome
in -X- _ I-Outcome
chemo- -X- _ I-Outcome
and -X- _ I-Outcome
castration-resistant -X- _ I-Outcome
prostate -X- _ I-Outcome
cancer -X- _ I-Outcome
models -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
vivo -X- _ I-Outcome
. -X- _ O

